Related Experiment Videos

A role of fatty acid oxidation in cardiac hypertrophy

R Bressler1, S Goldman

  • 1Department of Medicine, University of Arizona Health Sciences Center, Tucson.

Cardioscience
|September 1, 1993
PubMed

Insights

Inducing myocardial hypertrophy with a carnitine palmitoyl transferase I inhibitor helped prevent pathological heart dilation after a large myocardial infarction in rats. This intervention improved systolic function and reduced heart enlargement.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Myocardial infarction (MI) can lead to pathological cardiac remodeling, including left ventricular (LV) dilation, increasing risks of arrhythmias, heart failure, and sudden death.
  • Infarctions exceeding 20% of the LV induce minimal compensatory hypertrophy, leading to increased filling pressures and dilation.
  • Inadequate myocardial hypertrophy post-MI is hypothesized to drive progressive LV dilation.

Purpose of the Study:

  • To investigate if inducing additional myocardial hypertrophy using 2-tetradecylglycidic acid (TDGA) can prevent pathological LV dilation after a large MI in rats.
  • To assess the effects of TDGA-induced hypertrophy on cardiac function following a significant myocardial infarction.

Main Methods:

  • Rats underwent a large myocardial infarction (50% of LV).
  • Experimental groups received oral administration of 2-tetradecylglycidic acid, an inhibitor of carnitine palmitoyl transferase I, for 10 days post-infarction.
  • Hemodynamic parameters, including peak developed LV pressure, LV end-diastolic volume, and stroke volume, were measured.

Main Results:

  • TDGA treatment induced myocardial hypertrophy in both control and infarcted rats.
  • Infarcted rats treated with TDGA exhibited increased peak developed LV pressure and reduced LV end-diastolic volumes compared to untreated infarcted rats.
  • Stroke volume was maintained in the TDGA-treated infarcted group.

Conclusions:

  • Pharmacological induction of myocardial hypertrophy using a long-chain fatty acid oxidation inhibitor (TDGA) mitigated LV dilation post-large MI.
  • This approach demonstrated beneficial effects on systolic function, suggesting a potential therapeutic strategy for post-MI cardiac remodeling.

Related Concept Videos